Stock AnalizCONMED Corp CNMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 1987 · data as of November 13, 2026
CONMED Corp (CNMD) is a healthcare company listed in the US with a market value of about $1.5B. In the twelve months to September 30, 2026 it had revenue of $1.4B and net income of $73M, a net margin of 5.4%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is value (4/5); the weakest is future growth (1/5).
Key numbers: a P/E of 21.0, a price to free cash flow of 11.4, 5-year revenue growth of 10% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 5% below the current price.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- Positive free cash flow
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.4B | $1.3B | $1.2B | $1.0B | $1.0B | $862M | $955M | $860M | $796M | $764M |
| Net income | $73M | $47M | $132M | $64M | -$81M | $63M | $10M | $29M | $41M | $55M | $15M |
| Free cash flow | $133M | $151M | $154M | $106M | $12M | $97M | $52M | $75M | $58M | $53M | $25M |
| EPS (diluted) | $2.41 | $1.51 | $4.25 | $2.04 | $-2.68 | $1.94 | $0.32 | $0.97 | $1.41 | $1.97 | $0.52 |
| Net margin | 5.4% | 3.4% | 10.1% | 5.2% | -7.7% | 6.2% | 1.1% | 3.0% | 4.8% | 7.0% | 1.9% |
| ROIC | — | 3.5% | 8.5% | 5.3% | 3.0% | 6.3% | 2.5% | 4.8% | 5.1% | 3.3% | 2.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $46.83, 7% below the current price; targets range from $43.00 to $50.00; the consensus rating is “Hold”; expected EPS is $4.57 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is CONMED’s P/E ratio?
About 21.0, based on the last twelve months of diluted earnings per share (forward P/E about 11.0).
Is CONMED stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 5% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does CONMED pay a dividend?
Not currently.
Is CONMED a good stock to buy?
We do not give buy or sell advice. CONMED scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.